Aspen: The European Commission’s First Decision on Excessive Pricing in the Pharmaceuticals Sector

Kalpana Tyagi

doi:10.21552/core/2022/2/13

Aspen: The European Commission’s First Decision on Excessive Pricing in the Pharmaceuticals Sector

Kalpana Tyagi^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

On 10 February 2021, the Commission entered into a settlement decision with Aspen under Article 9 of Regulation 1/2003. The Commission investigated 'excessive pricing' by the South Africa-headquartered Aspen in six off-patent cancer drugs in the European Economic Area (EEA). These drugs had been off-patent for well over 50 years, and there seemed no rational prima facie justification for their unfairly high prices. This case note offers a critical discussion on the Commission’s case and Aspen’s well-planned strategy to systematically and uniformly increase prices across the Member States.

Original language	English
Pages (from-to)	173-179
Number of pages	7
Journal	European Competition and Regulatory Law Review
Volume	6
Issue number	2
DOIs	https://doi.org/10.21552/core/2022/2/13
Publication status	Published - 1 Jan 2022

Access to Document

10.21552/core/2022/2/13

https://www.researchgate.net/publication/359744045_Aspen_Commission's_first_on_excessive_pricing_in_the_pharmaceuticals_sectorLicence: CC BY

Cite this

@article{92b9102e628b4deab3e15e699d66ffb8,

title = "Aspen: The European Commission{\textquoteright}s First Decision on Excessive Pricing in the Pharmaceuticals Sector",

abstract = "On 10 February 2021, the Commission entered into a settlement decision with Aspen under Article 9 of Regulation 1/2003. The Commission investigated 'excessive pricing' by the South Africa-headquartered Aspen in six off-patent cancer drugs in the European Economic Area (EEA). These drugs had been off-patent for well over 50 years, and there seemed no rational prima facie justification for their unfairly high prices. This case note offers a critical discussion on the Commission{\textquoteright}s case and Aspen{\textquoteright}s well-planned strategy to systematically and uniformly increase prices across the Member States.",

author = "Kalpana Tyagi",

year = "2022",

month = jan,

day = "1",

doi = "10.21552/core/2022/2/13",

language = "English",

volume = "6",

pages = "173--179",

journal = "European Competition and Regulatory Law Review",

issn = "2510-3148",

publisher = "Lexxion Verlagsgesellschaft mbH",

number = "2",

}

TY - JOUR

T1 - Aspen

T2 - The European Commission’s First Decision on Excessive Pricing in the Pharmaceuticals Sector

AU - Tyagi, Kalpana

PY - 2022/1/1

Y1 - 2022/1/1

N2 - On 10 February 2021, the Commission entered into a settlement decision with Aspen under Article 9 of Regulation 1/2003. The Commission investigated 'excessive pricing' by the South Africa-headquartered Aspen in six off-patent cancer drugs in the European Economic Area (EEA). These drugs had been off-patent for well over 50 years, and there seemed no rational prima facie justification for their unfairly high prices. This case note offers a critical discussion on the Commission’s case and Aspen’s well-planned strategy to systematically and uniformly increase prices across the Member States.

AB - On 10 February 2021, the Commission entered into a settlement decision with Aspen under Article 9 of Regulation 1/2003. The Commission investigated 'excessive pricing' by the South Africa-headquartered Aspen in six off-patent cancer drugs in the European Economic Area (EEA). These drugs had been off-patent for well over 50 years, and there seemed no rational prima facie justification for their unfairly high prices. This case note offers a critical discussion on the Commission’s case and Aspen’s well-planned strategy to systematically and uniformly increase prices across the Member States.

UR - http://www.scopus.com/inward/record.url?scp=85135032605&partnerID=8YFLogxK

U2 - 10.21552/core/2022/2/13

DO - 10.21552/core/2022/2/13

M3 - Article

SN - 2510-3148

VL - 6

SP - 173

EP - 179

JO - European Competition and Regulatory Law Review

JF - European Competition and Regulatory Law Review

IS - 2

ER -

Aspen: The European Commission’s First Decision on Excessive Pricing in the Pharmaceuticals Sector

Abstract

Access to Document

Other files and links

Fingerprint

Cite this